🏛️ Verified NIH Record • Updated 2026-05-15
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) (NCT05431270)
🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: Phanes Therapeutics
🩺 Plain-English Summary (8th-Grade Level)
This is a first-in-human, Phase 1/2, open-label, study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Mavrostobart (PT199) alone and in combination with a PD-1 inhibitor or chemotherapy.
Who can join: Review the eligibility criteria below.
Location: Carolina BioOncology Institute — Huntersville, North Carolina
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (6 Sites)
- Carolina BioOncology Institute — Huntersville, North Carolina
- Sarah Cannon Research Institute University of Oklahoma — Oklahoma City, Oklahoma
- SCRI Oncology Partners — Nashville, Tennessee
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- Tranquility Research — Webster, Texas
- NEXT Oncology — Fairfax, Virginia
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.